RU2009140731A - Фармацевтические составы, содержащие молекулы ghrh - Google Patents

Фармацевтические составы, содержащие молекулы ghrh Download PDF

Info

Publication number
RU2009140731A
RU2009140731A RU2009140731/15A RU2009140731A RU2009140731A RU 2009140731 A RU2009140731 A RU 2009140731A RU 2009140731/15 A RU2009140731/15 A RU 2009140731/15A RU 2009140731 A RU2009140731 A RU 2009140731A RU 2009140731 A RU2009140731 A RU 2009140731A
Authority
RU
Russia
Prior art keywords
composition according
trans
ghrh
composition
cis
Prior art date
Application number
RU2009140731/15A
Other languages
English (en)
Russian (ru)
Inventor
Хелен ЛАУГРЕЙ (CA)
Хелен ЛАУГРЕЙ
Биеонг ЧАНГ (US)
Биеонг ЧАНГ
Original Assignee
Тератекнолоджиз Инк. (Ca)
Тератекнолоджиз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тератекнолоджиз Инк. (Ca), Тератекнолоджиз Инк. filed Critical Тератекнолоджиз Инк. (Ca)
Publication of RU2009140731A publication Critical patent/RU2009140731A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2009140731/15A 2007-04-04 2008-04-04 Фармацевтические составы, содержащие молекулы ghrh RU2009140731A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90998507P 2007-04-04 2007-04-04
US60/909,985 2007-04-04

Publications (1)

Publication Number Publication Date
RU2009140731A true RU2009140731A (ru) 2011-05-10

Family

ID=39827484

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2009140731/15A RU2009140731A (ru) 2007-04-04 2008-04-04 Фармацевтические составы, содержащие молекулы ghrh

Country Status (13)

Country Link
US (1) US20080249017A1 (https=)
EP (1) EP2142207A4 (https=)
JP (1) JP2010523501A (https=)
KR (1) KR20090130044A (https=)
CN (1) CN101678083A (https=)
AU (1) AU2008235215A1 (https=)
BR (1) BRPI0809441A2 (https=)
CA (1) CA2680329A1 (https=)
IL (1) IL200810A0 (https=)
MX (1) MX2009010675A (https=)
RU (1) RU2009140731A (https=)
WO (1) WO2008122118A1 (https=)
ZA (1) ZA200906179B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4778053B2 (ja) * 2005-07-14 2011-09-21 リセラ，インコーポレイテッド 局所的脂肪組織処置のための徐放性増強脂肪分解処方物
PL2077830T3 (pl) * 2006-10-17 2013-04-30 Lithera Inc Sposoby, kompozycje i formulacje do leczenia orbitopatii tarczycowej
US9132084B2 (en) 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
GB2487868B (en) * 2010-01-15 2014-12-10 Neothetics Inc Lyophilized cake formulations
JP5582983B2 (ja) * 2010-11-24 2014-09-03 楠本化成株式会社 水系沈降防止剤
US9597531B2 (en) 2010-11-24 2017-03-21 Neothetics, Inc. Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
JP2016027003A (ja) * 2012-11-20 2016-02-18 大蔵製薬株式会社 長期間安定なオランザピンの水性医薬製剤
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
CN113646327A (zh) 2019-03-29 2021-11-12 综合医院公司 用于治疗肝脏疾病的ghrh或其类似物
US20230270865A1 (en) * 2020-07-05 2023-08-31 Theratechnologies Inc. Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
WO2024133908A1 (en) * 2022-12-23 2024-06-27 Syna Therapeutics, S.L. Stable pharmaceutical compositions comprising romiplostim

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5137872A (en) * 1989-09-18 1992-08-11 Pitman-Moore, Inc. Growth hormone-releasing factor analogs
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
EP0880969A1 (en) * 1997-05-28 1998-12-02 Applied Research Systems ARS Holdings N.V. Pharmaceutical compositions of peptides having low solubility in physiological medium
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
FR2776520B1 (fr) * 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
WO2000006124A2 (en) * 1998-07-30 2000-02-10 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles
EP1064934A1 (en) * 1999-06-30 2001-01-03 Applied Research Systems ARS Holding N.V. GRF-containing lyophilized pharmaceutical composition
WO2001087322A2 (en) * 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
AU9558901A (en) * 2000-10-05 2002-04-15 Ares Trading Sa Regioselective liquid phase pegylation
CA2454587C (en) * 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
CA2472956A1 (en) * 2002-02-14 2003-08-21 Bayer Pharmaceuticals Corporation Formulation strategies in stabilizing peptides in organic solvents and in dried states
WO2004027064A2 (en) * 2002-09-18 2004-04-01 Centre Hospitalier De L'universite De Montreal (Chum) Ghrh analogues
AU2003229222B2 (en) * 2003-05-29 2009-11-12 Theratechnologies Inc. GRF analog compositions and their use
US7662393B2 (en) * 2004-04-07 2010-02-16 Ares Trading S.A. Liquid growth hormone formulation and method of use
EP1812048A4 (en) * 2004-10-20 2012-01-18 Theratechnologies Inc GH SECRETAGOGA AND ITS USE
CA2593112A1 (en) * 2005-01-21 2006-07-27 Alza Corporation Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion

Also Published As

Publication number Publication date
BRPI0809441A2 (pt) 2015-06-23
EP2142207A4 (en) 2013-01-16
CA2680329A1 (en) 2008-10-16
JP2010523501A (ja) 2010-07-15
AU2008235215A2 (en) 2011-02-24
EP2142207A1 (en) 2010-01-13
CN101678083A (zh) 2010-03-24
AU2008235215A1 (en) 2008-10-16
MX2009010675A (es) 2009-10-23
IL200810A0 (en) 2010-05-17
WO2008122118A1 (en) 2008-10-16
ZA200906179B (en) 2010-05-26
KR20090130044A (ko) 2009-12-17
US20080249017A1 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
RU2009140731A (ru) Фармацевтические составы, содержащие молекулы ghrh
DE69131317T2 (de) HIV-Proteaseinhibitoren
US20230120030A1 (en) Long-Acting Adrenomedullin Derivatives
KR101589191B1 (ko) 성장 호르몬의 분비를 촉진시키는 수용체 리간드의 약학 조성물
ES2259834T3 (es) Peptidos que contienen lisina para el tratamiento de la enfermedad coronaria.
US20110245173A1 (en) Long-Acting GLP-1 Derivatives, and Methods of Treating Cardiac Dysfunction
DE60130192T2 (de) Kahalalide f und verwandte verbindungen
EP0536245A1 (en) Novel, protracted insulin analogues
KR880001701A (ko) 신규한 펩티드
HU203480B (en) Process for producing parenteral pharmaceutical compositions containing somatostatin analogues as active components
ATE69821T1 (de) Grf-analoga.
CA2873553C (en) Use of modified vasoactive intestinal peptides in the treatment of hypertension
JP2010523501A5 (https=)
DE69424736T2 (de) Dem Motilin ähnliche Peptide mit hemmender Wirkung auf den gastrointestinalem Trakt
JP3131215B2 (ja) 新規インスリン誘導体
WO2011038066A4 (en) Novel npr-b agonists
DE69528531T2 (de) D-2-alkyltryptophan enthaltende polypeptide mit wachstumhormon freisetzender aktivitaet
WO2016047797A1 (ja) 注射用医薬組成物
KR20060126063A (ko) Ｐｔｈ, 완충제 및 안정제를 포함하는 안정한 ｐｔｈ조성물
JPH08501055A (ja) 神経ペプチドチロシンの生物学的機能を抑制する新規な分子
CA2487061A1 (en) Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin f2.alpha. receptor
CN1462277A (zh) 包含止痛肽的药物组合物
Elseviers et al. Evidence for the bioactive conformation in a cyclic hexapeptide analogue of somatostatin containing a cis-peptide bond mimic
RU2004139053A (ru) Иммуногенные конъюгаты
EP0477217B1 (en) Stabilized, potent grf analogs

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20120124